Literature DB >> 10068653

Vitronectin inhibits the thrombotic response to arterial injury in mice.

W P Fay1, A C Parker, M N Ansari, X Zheng, D Ginsburg.   

Abstract

Vitronectin (VN) binds to plasminogen activator inhibitor-1 (PAI-1) and integrins and may play an important role in the vascular response to injury by regulating fibrinolysis and cell migration. However, the role of VN in the earliest response to vascular injury, thrombosis, is not well characterized. The purpose of this study was to test the hypothesis that variation in vitronectin expression alters the thrombotic response to arterial injury in mice. Ferric chloride (FeCl3) injury was used to induce platelet-rich thrombi in mouse carotid arteries. Wild-type (VN +/+, n = 14) and VN-deficient (VN -/-, n = 15) mice, matched for age and gender, were studied. Time to occlusion after FeCl3 injury was determined by application of a Doppler flowprobe to the carotid artery. Occlusion times of VN -/- mice were significantly shorter than those of VN +/+ mice (6.0 +/- 1.2 minutes v 17.8 +/- 2.3 minutes, respectively, P < .001). Histologic analysis of injured arterial segments showed that thrombi from VN +/+ and VN -/- mice consisted of dense platelet aggregates. In vitro studies of murine VN +/+ and VN -/- platelets showed no significant differences in ADP-induced aggregation, but a trend towards increased thrombin-induced aggregation in VN -/- platelets. Purified, denatured VN inhibited thrombin-induced platelet aggregation, whereas native VN did not. Thrombin times of plasma from VN -/- mice (20.5 +/- 2.1 seconds, n = 4) were significantly shorter than those of VN +/+ mice (34.2 +/- 6.7 seconds, n = 4, P < .01), and the addition of purified VN to VN -/- plasma prolonged the thrombin time into the normal range, suggesting that VN inhibits thrombin-fibrinogen interactions. PAI-1-deficient mice (n = 6) did not demonstrate significantly enhanced arterial thrombosis compared with wild-type mice (n = 6), excluding a potential indirect antithrombin function of VN mediated by interactions with PAI-1 as an explanation for the accelerated thrombosis observed in VN -/- mice. These results suggest that vitronectin plays a previously unappreciated antithrombotic role at sites of arterial injury and that this activity may be mediated, at least in part, by inhibiting platelet-platelet interactions and/or thrombin procoagulant activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10068653

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen.

Authors:  H Ni; C V Denis; S Subbarao; J L Degen; T N Sato; R O Hynes; D D Wagner
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 2.  Thrombus formation in vivo.

Authors:  Bruce Furie; Barbara C Furie
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Serum vitronectin levels in patients with Behçet's disease.

Authors:  Ali Yalçındağ; Aslıhan Uzun; F Nilüfer Yalçındağ; Namık Delibaş
Journal:  Inflamm Res       Date:  2012-07-19       Impact factor: 4.575

4.  Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.

Authors:  Wende Hao; Xuhui Zhang; Bingshui Xiu; Xiqin Yang; Shuofeng Hu; Zhiqiang Liu; Cuimi Duan; Shujuan Jin; Xiaomin Ying; Yanfeng Zhao; Xiaowei Han; Xiaopeng Hao; Yawen Fan; Heather Johnson; Di Meng; Jenny L Persson; Heqiu Zhang; XiaoYan Feng; Yan Huang
Journal:  Tumour Biol       Date:  2016-01-11

5.  Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity.

Authors:  S Konstantinides; K Schäfer; S Koschnick; D J Loskutoff
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

6.  Nucleotide-binding oligomerization domain 2 receptor is expressed in platelets and enhances platelet activation and thrombosis.

Authors:  Si Zhang; Shenghui Zhang; Liang Hu; Lili Zhai; Ruyi Xue; Jianqin Ye; Leilei Chen; Guanjun Cheng; Jozef Mruk; Satya P Kunapuli; Zhongren Ding
Journal:  Circulation       Date:  2015-02-17       Impact factor: 29.690

Review 7.  Mice deficient in heparan sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes.

Authors:  Nicholas W Shworak; Sassan HajMohammadi; Ariane I de Agostini; Robert D Rosenberg
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

8.  Activity of MMP-19 inhibits capillary-like formation due to processing of nidogen-1.

Authors:  B Titz; S Dietrich; T Sadowski; C Beck; A Petersen; R Sedlacek
Journal:  Cell Mol Life Sci       Date:  2004-07       Impact factor: 9.261

9.  Sialylation of vitronectin regulates stress fiber formation and cell spreading of dermal fibroblasts via a heparin-binding site.

Authors:  Yasunori Miyamoto; Mio Tanabe; Kimie Date; Kanoko Sakuda; Kotone Sano; Haruko Ogawa
Journal:  Glycoconj J       Date:  2016-03-15       Impact factor: 2.916

10.  Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease.

Authors:  Hakan Ekmekci; Huseyin Sonmez; Ozlem B Ekmekci; Zeynep Ozturk; Nergiz Domanic; Emine Kokoglu
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.